← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Anteris Technologies Global Corp. (AVR) 10-Year Financial Performance & Capital Metrics

AVR • • Industrial / General
HealthcareMedical DevicesCardiovascular DevicesStructural Heart & Valve Devices
AboutAnteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.Show more
  • Revenue $3M -1.2%
  • EBITDA -$77M -63.6%
  • Net Income -$76M -65.8%
  • EPS (Diluted) -3.77 -194.5%
  • Gross Margin 46.84% +46.1%
  • EBITDA Margin -2843.69% -65.5%
  • Operating Margin -2899.45% -64.7%
  • Net Margin -2822.46% -67.7%
  • ROE -187.03% +43.2%
  • ROIC -
  • Debt/Equity 0.02 -73.6%
  • Interest Coverage -955.76 -33.2%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Share count reduced 43.6% through buybacks
  • ✓Trading at only 1.5x book value

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y-22.61%
TTM-21.09%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-18.59%

EPS CAGR

10Y-
5Y-
3Y-
TTM-81.73%

ROCE

10Y Avg-274.26%
5Y Avg-274.26%
3Y Avg-262.75%
Latest-183.95%

Peer Comparison

Structural Heart & Valve Devices
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
LIVNLivaNova PLC3.35B61.3352.878.66%-16.12%-18.79%4.06%0.51
ABTAbbott Laboratories216.14B124.3016.274.59%31.88%27.26%2.94%0.32
EWEdwards Lifesciences Corporation48.65B83.8412.038.57%23.19%13.37%0.6%0.07
AVRAnteris Technologies Global Corp.184.98M4.49-1.19-1.16%-39.42%-25.1%0.02

Profit & Loss

Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+5.46M5.83M3.2M2.73M2.7M
Revenue Growth %-0.07%-0.45%-0.15%-0.01%
Cost of Goods Sold+2.1M3.93M2.9M1.86M1.44M
COGS % of Revenue0.38%0.67%0.91%0.68%0.53%
Gross Profit+3.36M1.91M298.38K876.8K1.27M
Gross Margin %0.62%0.33%0.09%0.32%0.47%
Gross Profit Growth %--0.43%-0.84%1.94%0.44%
Operating Expenses+16.62M18.77M31.41M49.02M79.64M
OpEx % of Revenue3.05%3.22%9.81%17.92%29.46%
Selling, General & Admin2.63M9.14M15.21M17.05M0
SG&A % of Revenue0.48%1.57%4.75%6.23%-
Research & Development3.57M9.99M17.59M31.02M51.45M
R&D % of Revenue0.65%1.71%5.5%11.34%19.03%
Other Operating Expenses10.41M-364.5K-1.39M949.48K28.19M
Operating Income+-13.26M-16.86M-31.11M-48.14M-78.37M
Operating Margin %-2.43%-2.89%-9.72%-17.6%-28.99%
Operating Income Growth %--0.27%-0.85%-0.55%-0.63%
EBITDA+-12.68M-16.22M-30.34M-46.98M-76.86M
EBITDA Margin %-2.32%-2.78%-9.48%-17.18%-28.44%
EBITDA Growth %--0.28%-0.87%-0.55%-0.64%
D&A (Non-Cash Add-back)577.52K640.09K774.08K1.16M1.51M
EBIT-14.63M-16.14M-29.92M-46.7M-78.37M
Net Interest Income+-300.64K-965.64K-438.33K360.97K-82K
Interest Income068.55K210.38K428.06K0
Interest Expense300.64K1.03M648.71K67.09K82K
Other Income/Expense1.48M-310.48K550.48K1.38M2.4M
Pretax Income+-11.78M-17.17M-30.56M-46.76M-75.97M
Pretax Margin %-2.16%-2.95%-9.55%-17.1%-28.1%
Income Tax+00000
Effective Tax Rate %1%1%1%0.98%1%
Net Income+-11.78M-17.17M-30.56M-46.02M-76.29M
Net Margin %-2.16%-2.95%-9.55%-16.83%-28.22%
Net Income Growth %--0.46%-0.78%-0.51%-0.66%
Net Income (Continuing)-11.78M-17.17M-30.56M-46.76M-75.97M
Discontinued Operations00000
Minority Interest000-402.83K-79K
EPS (Diluted)+-0.33-0.48-0.85-1.28-3.77
EPS Growth %--0.45%-0.77%-0.51%-1.95%
EPS (Basic)-0.33-0.48-0.85-1.28-3.77
Diluted Shares Outstanding35.94M35.94M35.94M35.94M20.25M
Basic Shares Outstanding35.94M35.94M35.94M35.94M20.25M
Dividend Payout Ratio-----

Balance Sheet

Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+6.24M18.75M12.24M24.22M74.65M
Cash & Short-Term Investments3.36M15.46M9.29M21.03M70.46M
Cash Only3.36M15.46M9.29M21.03M70.46M
Short-Term Investments00000
Accounts Receivable652.39K1.85M1.51M1.85M383K
Days Sales Outstanding43.63115.94172.72246.2951.72
Inventory534.67K549.82K355.62K442.35K513K
Days Inventory Outstanding92.9651.1344.7286.9130.3
Other Current Assets1.7M060.13K61.66K2.66M
Total Non-Current Assets+3.51M2.68M3.75M6.31M6.05M
Property, Plant & Equipment1.87M1.92M3.14M5.48M5.86M
Fixed Asset Turnover2.91x3.04x1.02x0.50x0.46x
Goodwill00000
Intangible Assets1.09M763.64K607.35K410.15K189K
Long-Term Investments00000
Other Non-Current Assets548.3K00417.27K0
Total Assets+9.75M21.43M15.99M30.53M80.7M
Asset Turnover0.56x0.27x0.20x0.09x0.03x
Asset Growth %-1.2%-0.25%0.91%1.64%
Total Current Liabilities+6.04M10.2M6.05M9.46M16.56M
Accounts Payable581.87K2.23M1.73M3.14M5.89M
Days Payables Outstanding101.16207.27217.17616.671.5K
Short-Term Debt1.97M3.38M003K
Deferred Revenue (Current)00000
Other Current Liabilities2.82M1.81M1.57M1.77M1.44M
Current Ratio1.03x1.84x2.02x2.56x4.51x
Quick Ratio0.94x1.78x1.97x2.51x4.48x
Cash Conversion Cycle35.42-40.20.27-283.48-1.31K
Total Non-Current Liabilities+1.85M712.36K907.04K2.17M1.46M
Long-Term Debt00000
Capital Lease Obligations639.32K305.81K439.78K926.78K645K
Deferred Tax Liabilities00000
Other Non-Current Liabilities1.21M406.54K467.26K1.25M812K
Total Liabilities7.9M10.91M6.95M11.63M18.02M
Total Debt+2.92M4.14M952.79K1.6M1.4M
Net Debt-440.56K-11.32M-8.34M-19.43M-69.06M
Debt / Equity1.57x0.39x0.11x0.08x0.02x
Debt / EBITDA-----
Net Debt / EBITDA-----
Interest Coverage-44.11x-16.30x-47.96x-717.55x-955.76x
Total Equity+1.86M10.52M9.03M18.9M62.68M
Equity Growth %-4.67%-0.14%1.09%2.32%
Book Value per Share0.050.290.250.533.09
Total Shareholders' Equity1.86M10.52M9.03M19.3M62.76M
Common Stock106.97M141.47M169.79M217.33M4K
Retained Earnings-103.91M-123.51M-154.07M-200.1M-276.39M
Treasury Stock00000
Accumulated OCI-1.2M-7.75M-9.94M-9.56M-10.89M
Minority Interest000-402.83K-79K

Cash Flow

Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-11.08M-14.44M-29.42M-34.63M-61.24M
Operating CF Margin %-2.03%-2.48%-9.19%-12.66%-22.66%
Operating CF Growth %--0.3%-1.04%-0.18%-0.77%
Net Income-11.78M-17.17M-30.56M-46.76M-76.29M
Depreciation & Amortization1.01M640.09K774.08K1.16M1.97M
Stock-Based Compensation323.98K254.85K2.94M5.76M0
Deferred Taxes00000
Other Non-Cash Items-6.01M861.55K-817.14K1.23M14.06M
Working Capital Changes5.38M976.4K-1.75M3.99M-982K
Change in Receivables4.53M85.45K-533.8K-345.01K-911K
Change in Inventory862.78K-15.71K194.2K-86.72K-71K
Change in Payables00000
Cash from Investing+5.99M-886.07K-992.57K-2.58M-2.28M
Capital Expenditures-222.45K-572.87K-1.57M-2.39M-2.27M
CapEx % of Revenue0.04%0.1%0.49%0.87%0.84%
Acquisitions-----
Investments-----
Other Investing6.21M-1.4K582.2K19.59K-14K
Cash from Financing+1.46M27.42M23.27M49.34M112.83M
Debt Issued (Net)-----
Equity Issued (Net)-----
Dividends Paid00000
Share Repurchases-----
Other Financing1.74M-1.23M-1.05M-2.68M115.07M
Net Change in Cash-----
Free Cash Flow+-11.3M-15.02M-31.08M-37.03M-63.51M
FCF Margin %-2.07%-2.58%-9.71%-13.54%-23.5%
FCF Growth %--0.33%-1.07%-0.19%-0.72%
FCF per Share-0.31-0.42-0.86-1.03-3.14
FCF Conversion (FCF/Net Income)0.94x0.84x0.96x0.75x0.80x
Interest Paid203.2K50.27K33.4K38.47K0
Taxes Paid00000

Key Ratios

Metric20202021202220232024
Return on Equity (ROE)-634.53%-277.38%-312.54%-329.54%-187.03%
Return on Invested Capital (ROIC)--4070.26%--45271.86%-
Gross Margin61.53%32.68%9.32%32.06%46.84%
Net Margin-215.78%-294.5%-954.91%-1682.81%-2822.46%
Debt / Equity1.57x0.39x0.11x0.08x0.02x
Interest Coverage-44.11x-16.30x-47.96x-717.55x-955.76x
FCF Conversion0.94x0.84x0.96x0.75x0.80x
Revenue Growth-6.83%-45.1%-14.56%-1.16%

Frequently Asked Questions

Growth & Financials

Anteris Technologies Global Corp. (AVR) reported $2.1M in revenue for fiscal year 2024. This represents a 61% decrease from $5.5M in 2020.

Anteris Technologies Global Corp. (AVR) saw revenue decline by 1.2% over the past year.

Anteris Technologies Global Corp. (AVR) reported a net loss of $84.3M for fiscal year 2024.

Dividend & Returns

Anteris Technologies Global Corp. (AVR) has a return on equity (ROE) of -187.0%. Negative ROE indicates the company is unprofitable.

Anteris Technologies Global Corp. (AVR) had negative free cash flow of $79.4M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.